This site is intended only for healthcare professionals resident in Egypt
Nimenrix is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal disease caused by Neisseria meningitidis groups A, C, W-135, and Y. 2
In 2018, Nimenrix® was introduced into the Netherlands National Immunisation Programme for used in toddlers (aged 14 months) and adolescents (14–18 years). Significant disease reduction was demonstrated in both vaccinated and unvaccinated populations.2
Since adolescents have high carriage rates, vaccinating them can also help protect the larger population. Nimenrix® represents an option for the prevention of meningococcal disease in populations globally.3
Approval Code: BF0098OA686/052023
Invalidation date: 10/05/2025
Adverse events should be reported. Adverse events can be reported to [email protected]
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
The product information provided in this site is intended only for Healthcare Professionals of Egypt. The products discussed herein may have different product labeling in different countries.
Copyright © 2023 Pfizer biopharmaceutical LLC. All rights reserved.
These pages are not intended for patients or members of the general public. This portal contains healthcare promotional content.
If you select ‘No’, you will be redirected to Pfizer.com, the global Pfizer website.
I confirm that I am a healthcare professional resident in Egypt.